Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

35.10 +0.06 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,110,428
Open 35.13
Bid (Size) 34.63 (1)
Ask (Size) 35.30 (5)
Prev. Close 35.04
Today's Range 34.95 - 35.19
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
 
Via Benzinga
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat

Performance

YTD
-0.54%
-0.54%
1 Month
+0.80%
+0.80%
3 Month
+0.09%
+0.09%
6 Month
+22.47%
+22.47%
1 Year
-19.07%
-19.07%

More News

Read More
Recent Stock Purchases For March 2023
Via Talk Markets
GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms
Via Investor's Business Daily
This Is What Whales Are Betting On GSK
Via Benzinga
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Daily Stock Analysis: GSK
Via Talk Markets
How Is The Market Feeling About GSK?
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
Via InvestorPlace
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
Via The Motley Fool
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
Via Benzinga
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
From GSK plc
Via Business Wire
3 High Dividend Stocks With Attractive Total Return Potential
Via InvestorPlace
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
Via Investor's Business Daily
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
Via The Motley Fool
March 2023 Stock Considerations
Via Talk Markets
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
Via Benzinga
3 Crucial Things to Know About Moderna Right Now
Via The Motley Fool
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
Via Benzinga
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Intel and 9 Other Companies With Dividend Cuts in 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.